GGrantIndex
← Leaderboards

Sattva S Neelapu

University Of Tx Md Anderson Can Ctr

$3,334,171
Attributed
$5,555,824
Total exposure
4
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.1M · FY200725
$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$5,555,824 · 4

By mechanism

R01$4,443,307 · 2
R21$568,197 · 1
K23$544,320 · 1

Top collaborators

Most similar at University Of Tx Md Anderson Can Ctr

Same institution · by research overlap

Others in their field

Top investigators on “Tumor

Research focus

TumorResponseCellsImmunotherapyGenerationsProteinsMelanomaRelapseImmune ResponseLymphomaB-LymphocytesT-LymphocyteImmuneDisease RemissionMolecularImmunogenicImmunoglobulin IdiotypesPre-ClinicalFollicular LymphomaImmunologic MonitoringMalignant NeoplasmsDisease-Free SurvivalCancer PatientB-Cell Lymphomas

Grant awards (14)

[18F]4FN PET Imaging of Innate Immunity Activation During Immunotherapy-Induced Adverse Events$1,109,154
R01 · FY2025 · CA
[18F]4FN PET Imaging of Innate Immunity Activation During Immunotherapy-Induced Adverse Events$516,653
R01 · FY2024 · CA
[18F]4FN PET Imaging of Innate Immunity Activation During Immunotherapy-Induced Adverse Events$561,726
R01 · FY2023 · CA
[18F]4FN PET Imaging of Innate Immunity Activation During Immunotherapy-Induced Adverse Events$526,490
R01 · FY2022 · CA
Predictors of clinical outcome after therapeutic vaccination in follicular lympho$274,863
R01 · FY2014 · CA · contact PI
Predictors of clinical outcome after therapeutic vaccination in follicular lympho$465,019
R01 · FY2013 · CA · contact PI
Predictors of clinical outcome after therapeutic vaccination in follicular lympho$494,701
R01 · FY2012 · CA · contact PI
Predictors of clinical outcome after therapeutic vaccination in follicular lympho$494,701
R01 · FY2011 · CA · contact PI
Enhancing antitumor immunity with anti-PD-1 antibody in follicular lymphoma.$279,772
R21 · FY2011 · CA · contact PI
Enhancing antitumor immunity with anti-PD-1 antibody in follicular lymphoma.$288,425
R21 · FY2010 · CA · contact PI
Antigen Discovery and Development of Tumor-Specific Lymphoma Immunotherapy$136,080
K23 · FY2010 · CA · contact PI
Antigen Discovery and Development of Tumor-Specific Lymphoma Immunotherapy$136,080
K23 · FY2009 · CA · contact PI
Antigen Discovery and Development of Tumor-Specific Lymphoma Immunotherapy$136,080
K23 · FY2008 · CA · contact PI
Antigen Discovery and Development of Tumor-Specific Lymphoma Immunotherapy$136,080
K23 · FY2007 · CA · contact PI